Yelena Janjigian, Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, shared a post by Memorial Sloan Kettering Cancer Center, adding:
“FDA approval of perioperative durvalumab is sinking in today as I’m in clinic. Grateful for the incredible team behind this – it truly takes a village. Proud of everyone pictured here who helped make this possible to help patients all over the world. The best is yet to come.”
Quoting Memorial Sloan Kettering Cancer Center‘s post:
“A new FDA approval gives hope to people with stomachcancer and esophaguscancer. The clinical trial that resulted the approval, led by Yelena Janjigian and researchers at MSK, investigated using the immunotherapy treatment durvalumab (INFINZI) in combination with a standard-of-care chemotherapy regimen before and after surgery. The success of the trial led the FDA to approve the use of the treatment in people with early stage gastric and gastroesophageal cancers, making durvalumab the first and only immunotherapy approved for these patients before and after surgery.
Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology
